The License Behind the Treatment: Med Spas, IV Hydration, and the New Era of Professional Licensing Investigations

Why nurses, nurse practitioners, physician assistants, medical directors, and clinic owners face increasingly complex regulatory questions, and how clear documentation, informed preparation, and independent counsel can help protect both patients and careers.

By The BoardWise Team

October 31, 2026

Research & Insights | Medical Aesthetics | IV Hydration | Professional Licensing

A fast-growing industry, a deeply personal professional risk

A nurse starts a mobile IV hydration business after years of clinical experience. A nurse practitioner joins an aesthetics practice. A physician agrees to serve as the medical director for a wellness clinic. Another clinician begins administering injectable treatments in a polished retail environment that looks nothing like a traditional medical office.

Then a complaint arrives: perhaps a patient questions an adverse event, a former employee alleges that treatment was provided without proper orders, a pharmacy board asks about how an infusion was prepared, or a nursing board raises concerns about scope of practice.

To the individual professional, the matter may feel like a dispute over a single encounter or operating procedure. To regulators, however, the questions can implicate prescribing, delegation, nursing standards, drug preparation, patient assessment, professional supervision, and advertising, sometimes across several boards at once.

A medspa may have the atmosphere of a consumer wellness business, but its clinical activities remain subject to the laws governing medicine, nursing, and pharmacy. And a complaint is not a finding of wrongdoing. The response still deserves the same care and organization as the clinical work under examination.

BoardWise exists to help licensed professionals understand licensing processes, organize accurate records, prepare clear correspondence, and recognize when qualified legal advice is warranted. The need for this kind of support is increasingly apparent in medical aesthetics and elective IV hydration.

1. The sector is growing, and regulators are noticing

The American Med Spa Association's State of the Industry report describes a U.S. medical aesthetics industry exceeding $17 billion in annual revenue, with more than $1 billion in yearly growth. Those figures are industry-association estimates, not a federal government census, and are not a count of IV hydration clinics specifically. Still, they illustrate the commercial scale of a sector that brings clinical services into retail, mobile, and wellness settings.

California provides more direct evidence of enforcement pressure. In its FY 2026–27 Board of Registered Nursing investigations budget proposal, the board requested eight additional special investigators, citing increased complaints and growing investigative complexity. According to the document, between fiscal 2020–21 and 2024–25:

Source: California Department of Consumer Affairs/Board of Registered Nursing, FY 2026–27 budget change proposal, workload history table, page 3.

The board characterizes the increase in pending unassigned investigations as 193%, with referrals to its investigations division increasing about 64%. Importantly, those are measures of its overall workload. They are not medspa-specific complaint or disciplinary rates.

What makes the report especially significant is its explanation of the pressure. The board states that medspa and IV hydration matters can be multi-subject, resource-intensive investigations and says it authorized a Med Spa/IV Hydration Task Force involving other professional boards and Department of Consumer Affairs units. Its 2024–25 annual reporting also describes the continuing task force and a focus on negligent preparation and administration of IV medications.

The board's 2026 Sunset Review identifies complaints involving nurses allegedly performing compounding activities beyond their authority, and notes that investigators may have difficulty observing what occurs behind closed clinic doors. These official statements support the conclusion that medspas and IV clinics are a concrete regulatory priority, but they do not permit a reliable estimate of the industry's overall violation rate.

2. Why a single clinic can attract multiple regulatory agencies

The regulatory challenge is structural. A medspa or IV clinic is usually a business entity, but the services it offers may be performed by individuals whose permissions are defined by distinct professional licenses.

A clinic might employ a physician, an advanced practice registered nurse (APRN), a physician assistant (PA), a registered nurse (RN), a licensed practical/vocational nurse, estheticians, and nonclinical workers. The authority of each person depends on jurisdiction, credentials, scope of practice, required supervision, and the actual procedure.

Consider the different questions regulators might ask:

• Medical board: Who evaluated the patient? Who determined the treatment? Was the prescribing or delegation lawful? Did the physician or other prescriber provide required oversight?
• Nursing board: Did the RN or APRN practice within the relevant scope? Were orders valid? Was the administration clinically appropriate and documented?
• Pharmacy board: Who obtained, stored, compounded, mixed, dispensed, or labeled the drug? Were the sources and sterile procedures lawful?
• Federal authorities: Were injectable products lawfully marketed and prepared? Were health-benefit claims truthful and substantiated?

This overlapping framework is not merely hypothetical. The FDA's account of its 2023 intergovernmental drug-compounding meeting describes regulators discussing IV clinic problems involving prescriptions, product sourcing, licensing, and collaboration among pharmacy, nursing, and medical boards. The FDA later stated that it was encouraging such joint work on IV hydration risks in its published responses to meeting action items.

A regulator can investigate the conduct of an individual licensee while another agency examines a pharmacy transaction or business operation. Professionals should not assume a favorable result with one agency automatically resolves another agency's concerns.

3. Texas shows why the exact procedure and professional license matter

Texas has enacted an especially clear example of targeted regulation. Texas Occupations Code Chapter 172, added by House Bill 3749 and effective September 1, 2025, specifically addresses elective intravenous therapy as defined by the statute. It describes services sought to relieve temporary discomfort or improve temporary wellness, outside certain traditional healthcare facilities.

The law specifies which professionals may be delegated the ordering or administration of elective IV therapy, subject to physician supervision and applicable prescribing laws. The Texas Medical Board's IV hydration FAQ explains that elective IV therapy must be ordered by a physician or an appropriately supervised PA or APRN, and administration must be by qualified licensed clinical personnel.

The Texas Board of Nursing's nursing practice FAQ further explains that RNs may administer elective IV hydration under appropriate physician delegation and orders, but licensed vocational nurses, EMTs, paramedics, and unlicensed personnel may not be delegated these elective services under the 2025 law. This is not a general prohibition on LVNs participating in all medically indicated IV therapy in traditional settings; the board specifically distinguishes those circumstances.

For a nurse entrepreneur, the business-ownership question is separate from the practice question. Texas nursing regulators explain that nursing law does not categorically forbid a nurse from owning a business, but ownership alone does not grant authority to diagnose, prescribe, delegate, or perform every clinical service sold by that business.

The implication: A proper response to a Texas IV complaint must begin with the actual service, date, patient-specific order, personnel involved, and regulatory setting. Broad assertions that a nurse is “IV certified” or that a clinic has a “medical director” do not, by themselves, establish compliance with Chapter 172.

4. Virginia's October 2026 guidance draws unusually specific lines

On October 8, 2026, Virginia's Department of Health Professions made effective Guidance Document 76-1: Regulatory Considerations for IV Hydration Clinics and Med Spas, a joint guidance document applying across the agency's boards.

The eight-page official guidance illustrates the compliance questions now confronting operators:

• A properly authorized prescriber must evaluate the patient and issue patient-specific orders consistent with Virginia law.
• A menu selection, short questionnaire, or generic protocol does not replace the clinical evaluation required for elective treatments.
• Nurses and nonlicensed staff cannot independently diagnose or select prescription IV therapies in the manner described as prohibited by the guidance.
• Medical directors and other delegating clinicians retain responsibilities connected to oversight, credentials, training, and availability.
• Medication sourcing, preparation, storage, consent, and records are part of the regulatory picture.
• Telehealth may be available when it satisfies professional and legal standards; a questionnaire alone is not enough to establish a practitioner-patient relationship under the guidance.

The Virginia document also draws a meaningful distinction between compounding and certain authorized mixing, dilution, or reconstitution. It explains that the law, applicable pharmacy standards, and specific circumstances matter. A clinician should not assume that placing ingredients into an IV bag is legally interchangeable with routine medication administration.

Virginia's guidance is not a national rule. Other states permit different practice arrangements, may rely on different statutory definitions, and may allow certain standing orders under specifically authorized circumstances. That is precisely why generic online advice can be dangerous in this area.

5. California medical-spa rules provide a second warning about scope

In its Medical Spas consumer guidance, the Medical Board of California explains that procedures involving injections, lasers, and other medical-level cosmetic treatments must be provided by appropriately qualified medical personnel. The board contrasts those services with superficial esthetic treatments that licensed cosmetologists may perform.

The California Board of Registered Nursing's enforcement materials similarly identify the need to distinguish alleged violations from issues outside its authority. Its complaint-process page identifies possible allegations including gross negligence, unprofessional conduct, and unlicensed activity, and states that complaints outside its jurisdiction may be referred to other agencies.

An esthetician, RN, APRN, and physician do not hold interchangeable authorizations. Nor does an employee's job title or a weekend certification course automatically expand the scope granted by state law.

That does not mean a medspa employee has violated a rule every time someone raises a concern. It means the response must identify who did what, under whose authority, with which documentation, at what time, and under which state's actual requirements.

6. Drug quality and sterile preparation are not secondary details

The question “Who mixed the IV bag?” may be one of the most consequential questions in an investigation.

The CDC's safe-injection guidance emphasizes aseptic technique, single-patient use of syringes and appropriate infusion supplies, clean medication-preparation areas, and proper handling of single-dose containers. It also explains that certain forms of mixing or preparing medications fall within sterile-compounding standards.

The CDC's updated outpatient infection-prevention guidance describes foundational expectations applicable to ambulatory settings. A luxury interior or retail business model does not diminish those patient-safety obligations.

Federal oversight is increasingly specific. In an August 27, 2026 alert, FDA reported awareness of adverse events in at least 30 patients following administration of IV glutathione products compounded using a dietary-supplement-grade ingredient. The agency described symptoms consistent with endotoxin exposure, including fever and sepsis-like reactions, some requiring hospitalization.

Those reports should not be construed as evidence that all IV glutathione preparations or elective infusions caused those harms. They concern specific compounded products and a supply-chain quality problem. But the lesson is clear: ingredient quality and compounding controls can have immediate patient-safety consequences.

FDA has separately cautioned against using food-grade NAD+ ingredients in sterile IV preparations. Food-grade or supplement-grade labeling is not a substitute for standards applicable to injectable drugs.

A licensing response involving medication preparation may therefore require more than an explanation of the clinician's intentions. It may require documentation of sourcing, orders, lot numbers, preparation roles, storage, training, adverse events, and any corrective measures.

7. Federal enforcement can extend beyond an individual license

An October 13, 2026 FDA warning letter to Calibrate IV Hydration addressed marketing of certain umbilical-cord-derived and exosome products as unapproved drugs and unlicensed biological products. It is a concrete recent example of a business with an IV hydration identity facing federal scrutiny.

Importantly, the letter concerns those specific biologic products and claims, not the proposition that routine hydration infusions are categorically unlawful. The agency asked the recipient to address the cited concerns and provide supporting documentation.

The Federal Trade Commission also regulates deceptive health claims. Its Health Products Compliance Guidance requires marketers to possess suitable support for objective claims about health benefits and safety. An earlier FTC enforcement action involving IV cocktail marketing illustrates how assertions that elective infusions treat serious diseases can prompt scrutiny.

Marketing copy, intake questionnaires, treatment menus, consent materials, and clinician advertising can all become evidence in a regulatory review. Professionals should resist the false distinction between “marketing” and “clinical practice” when an advertised claim implies a medical indication or standard of treatment.

8. The most common categories of professional exposure

There is no comprehensive national database establishing the relative frequency of every medspa or elective IV violation. Nonetheless, official state guidance, FDA materials, and nursing-board procedures identify recurring areas that warrant attention:

These categories should be treated as an issue-spotting framework, not a claim that every clinic faces every risk or that a specific business is likely to be sanctioned.

9. What happens after a complaint is filed?

A complaint is usually only the beginning of a regulatory process. In California, the Board of Registered Nursing's official enforcement description organizes its work into complaint intake, investigation, legal action, and probation monitoring.

The board may initially determine that an allegation is outside its jurisdiction. Other complaints may be reviewed by nursing consultants, referred for investigation, closed when a violation is not substantiated, or advanced to legal proceedings.

Its enforcement FAQs distinguish outcomes such as closure without substantiation, closure without formal charges despite an issue being identified, citation and fine, and filing of a formal accusation. Formal proceedings may involve a hearing or negotiated agreement. Timeframes depend on jurisdiction, type of case, and evidence.

The California board also explains that some case information remains confidential during investigations but that formal accusations or discipline can become public. Thus, a response may affect both legal outcomes and reputational interests.

Do not mistake an initial investigative contact for a determination of guilt. Do not mistake the absence of formal charges for universal exoneration. A professional's immediate task is to understand the document, identify the deadline, preserve evidence, and assess the legal stakes.

In serious matters, possible patient harm, fraud allegations, criminal exposure, threatened suspension, or proposed consent orders, qualified legal counsel should be considered early, before making consequential admissions or accepting settlement terms.

10. What makes a response stronger, and what can make it worse

Regulators exist to protect the public. A credible response should help the agency understand whether care was safe, authorized, and documented, while respecting that mandate.

An effective process begins with evidence, not persuasion:

• Identify the notice precisely. A request for records, interview request, investigation notice, proposed citation, formal accusation, or federal warning letter may each carry different rights and deadlines.
• Create a chronology. Establish the date of the patient evaluation, order, preparation, treatment, monitoring, and follow-up from original records.
• Separate roles. Identify what the prescriber, supervising professional, treating RN, pharmacy, business owner, and other personnel actually did.
• Document clinical authority. Retain the relevant licenses, orders, signed agreements, applicable policies, and contemporaneous communication records.
• Preserve underlying evidence. Do not alter charts retrospectively, delete messages, rewrite protocols as though they had always existed, or encourage others to align testimony.
• Address each allegation. Respond to the substance with accurate facts rather than a generalized statement of professional competence.
• Document legitimate corrections. If an identified process needs improvement, record what changed, who authorized it, when it happened, and how patient safety is being monitored.
• Seek independent review. An attorney with the appropriate jurisdictional experience can assess statements, licensing consequences, privilege, and any obligations to other agencies or insurers.

A defensive response that blames a patient, omits clinical records, or assumes the medical director is solely responsible for everything can make an already difficult situation harder to understand. Conversely, an overly eager response can create unnecessary admissions. Accuracy and appropriate legal review matter more than rhetoric.

If patient harm or an ongoing unsafe practice may be occurring, immediate clinical safety measures and any legally required reporting take priority over preparing marketing-friendly explanations.

11. Favorable resolution does not always mean dismissal

Depending on the facts and law, potential licensing outcomes can include closure without substantiated findings, corrective education, a citation, an agreed order, probation conditions, limits on practice, suspension, or revocation. Some matters are referred to other agencies. These outcomes differ materially in their consequences and public visibility.

The California Board of Registered Nursing's disciplinary guidance identifies factors it considers in discipline, including seriousness, recency, evidence of rehabilitation, current ability to practice safely, mitigating factors, and disciplinary history. It also explains the significance of stipulated agreements, probation, suspension, and related dispositions.

A favorable outcome should be understood as a fair, lawful, evidence-based, and proportionate resolution, not necessarily the absence of accountability where genuine violations occurred.

For example, if clinical records establish that a nurse did not administer an alleged treatment, a well-supported factual response may assist the board in evaluating whether the allegation is substantiated. If a documented error occurred, evidence of genuine remediation may be relevant to assessment of safety and proportionality. Neither scenario establishes what the board must decide.

No independent comparative study is presented in this article demonstrating that BoardWise users in medspa or IV cases receive higher dismissal rates or lower penalties than comparable nonusers. BoardWise should be evaluated on the quality and usefulness of its process, not on an invented probability of winning.

12. Why BoardWise is well-positioned to help

BoardWise was designed for professionals confronting licensing matters, not for performing clinical care or issuing medical orders. Its strengths are closely matched to the paperwork and process challenges emerging in medical aesthetics and elective IV therapy.

Understand the state, license, and type of notice

BoardWise offers educational workflows and resources specific to state, profession, and issue. That matters when the same IV procedure can involve different legal authority and delegation rules in Texas, Virginia, and California.

The platform can help users begin with the right questions and flag procedural topics requiring verification. It is not a substitute for checking the current official notice, applicable law, and professional-board instructions.

Turn scattered records into a usable chronology

A clinic investigation may implicate appointment records, an EHR, medication orders, dispensing records, vendor invoices, treatment menus, consent forms, incident reports, and communications. BoardWise supports timeline-building, document organization, and structured correspondence so professionals can identify what evidence is relevant to each allegation.

Improve the clarity of drafts

BoardWise offers guided drafting, supporting-document checklists, and safeguards intended to catch missing context, combative phrasing, unnecessary unsupported claims, and incomplete remediation records. A structured draft still requires fact checking by the person who knows the case and legal review where warranted.

Provide a privacy-focused workspace

BoardWise describes its model as Zero Sensitive Data Retention: sensitive case details are processed in the user's browser rather than stored as persistent case records on BoardWise servers. This approach is intended to limit retention of sensitive licensing information. Users should separately assess the privacy practices of any external services or attorneys they choose to engage. Browser-side processing is not a guarantee of privilege or absolute security.

Make independent attorney review easier to access

When the matter requires legal interpretation or defense, BoardWise's independent Attorney Network offers an optional route to limited-scope document review, subject to jurisdiction, availability, and the attorney's independent engagement with the client. BoardWise is not a law firm and does not itself provide legal advice.

Support the full trajectory of a matter

The platform supports investigation correspondence, document preparation, corrective-action plans, hearing preparation, agreement review workflows, probation-related materials, and certain follow-up requests. The aim is to help professionals remain organized as their matters develop, not to automate legal judgments or interfere with regulators.

Explore the BoardWise intake workflow.

13. Three examples: what organized support could look like

These are hypothetical illustrations, not real BoardWise case studies or claimed outcomes.

A Texas mobile IV hydration nurse

An RN receives a board inquiry after a mobile infusion visit. The questions concern who evaluated the patient, who ordered the infusion, and whether appropriate delegation was in place.

BoardWise can help categorize the notice, build a dated chronology, gather the provider order, treatment record, supervisory agreement, and relevant communications, and prepare a clear factual draft. A qualified attorney can assess whether Texas Chapter 172 and the professional practice rules were satisfied and advise on the response.

The goal is not to create a compliant order after the fact. It is to accurately present what existed at the time and address any legitimate concerns.

A California aesthetics injector

An RN receives questions about cosmetic injections and clinic supervision after a patient complaint. The nurse worked alongside other practitioners, and the documentary record includes standing procedures, appointment notes, and messages involving the supervising clinician.

A structured workflow helps the RN separate actual acts from assumptions, link records to each allegation, and avoid a response that relies only on vague phrases such as “under medical direction.” Where legal or safety concerns are serious, independent counsel can evaluate the professional's rights and obligations.

A Virginia medspa with questions about IV preparation

A clinic receives questions about how vitamin-containing infusions were prepared, which employees handled ingredients, and how patients received individualized treatment decisions.

BoardWise can help the involved licensees organize role descriptions, medication purchase records, treatment notes, training evidence, and timelines. The Virginia 2026 joint guidance provides an important starting point for identifying the likely issues; it does not substitute for qualified interpretation of the particular facts. Corrective measures, if needed, should be real, timely, and documented rather than retroactively invented.

In every example, the professional supplies the facts, counsel addresses legal questions where engaged, and the regulator retains the authority to reach the outcome.

14. Better organized responses may also help regulators

The California board's request for additional investigators and its description of multi-subject medspa cases underscore the administrative burden of these investigations. Regulators may need records from multiple clinicians, pharmacies, businesses, and third parties.

A complete, indexed, internally consistent response can be more useful than an unstructured collection of screenshots and assertions. In principle, clear submissions could reduce requests for additional material, help investigators identify relevant evidence, and make factual disagreements easier to isolate.

That proposition is plausible but not yet proven as a BoardWise-specific efficiency outcome. Any agency partnership or pilot should measure completeness, time to receive requested records, staff follow-up requests, procedural compliance, and user understanding while preserving due process and the agency's independence.

A technology platform should not determine who is disciplined, suppress complainant rights, or promise preferred outcomes. The public-protection mission remains with duly authorized regulators.

15. A practical first-response checklist

If you have received a notice from a licensing board, medical board, pharmacy board, or other agency involving a medspa or elective IV clinic:

1. Read the whole notice and determine its procedural stage. Identify the named licensee, issuing agency, allegations, requested records, and deadline.

2. Preserve originals immediately. Retain the actual chart, original orders, messaging, advertisements, medication records, staffing schedules, and supervisory agreements.

3. Identify potential immediate safety obligations. If any unsafe practice is ongoing, address it through appropriate clinical leadership and comply with reporting duties.

4. Do not guess about scope or delegation. Check the state's current statute, board rules, and any relevant profession-specific guidance.

5. Separate patient care facts from business ownership facts. Both may matter, but different laws govern them.

6. Create an allegation-to-evidence map. Link each question to the documents that can accurately answer it; note genuine gaps rather than filling them with assumptions.

7. Avoid informal admissions or retaliatory communications. Be truthful and professional, and seek advice on interviews, compelled responses, or settlement discussions when appropriate.

8. Review insurer and employer notice obligations. Policy terms and contractual obligations may set separate timelines.

9. Obtain qualified counsel where needed. Particularly for severe patient harm, criminal implications, formal accusations, or proposed restrictions.

10. Keep copies of what was actually submitted and when. Retain delivery confirmations and any subsequent correspondence.

This list is for general preparation, not an instruction to withhold required information, violate lawful orders, or delay urgent patient-safety action.

16. Frequently asked questions

Can an RN open an IV hydration or medical aesthetics business?

Business ownership and authorization to practice medicine, nursing, or pharmacy are separate questions. Some states permit nurse-owned businesses while placing limits on who may evaluate, order, prepare, or administer treatments. Texas expressly distinguishes ownership from clinical authorization in its nursing practice FAQ. An individual business model requires state-specific review.

Does having a medical director make every treatment arrangement lawful?

No. The title itself does not establish that patient evaluation, prescribing, delegation, scope, and supervision requirements have been satisfied. Virginia's October 2026 guidance makes the distinction especially clear.

Can a patient choose an IV infusion from a menu?

Advertising a menu does not replace medical evaluation or an authorized order. Virginia states that questionnaires or self-selection alone cannot establish the required patient-specific treatment decision in the circumstances addressed by its guidance. Other states' rules must be examined independently.

Can LVNs or paramedics administer elective IV hydration in Texas?

Under Texas's 2025 elective IV therapy law, the Board of Nursing states that LVNs, paramedics, EMTs, and unlicensed staff cannot be delegated those elective services. This should not be generalized to all IV treatment in traditional medical settings or other states. See the Texas nursing FAQ.

Is every IV bag with added vitamins legally “compounded”?

The classification depends on statutory definitions, the particular preparation and professional authority, and applicable pharmacy and sterile-preparation standards. Virginia expressly addresses adding ingredients to IV fluids, while the CDC explains sterile compounding considerations. Do not assume a national one-size-fits-all answer.

Does a licensing complaint mean the professional will lose their license?

No. Complaint intake, investigation, and formal discipline are separate steps. Outcomes vary by agency and evidence. A serious complaint should still be handled promptly, since timelines and rights can matter greatly.

Can BoardWise guarantee a dismissal or reduced penalty?

No. BoardWise can help with education, organization, drafting, and access to independent attorneys. Only the relevant agency or adjudicator can decide a licensing case, and the legal outcome depends on the facts and governing law.

17. The future: protecting patients without leaving professionals to navigate alone

Growth in medical aesthetics and IV hydration has created legitimate opportunities for qualified clinicians and entrepreneurs. It has also created unfamiliar questions at the intersection of healthcare regulation, retail operations, sterile preparation, and professional licensing.

Regulatory oversight is essential where patients may face unsafe, unauthorized, or deceptively marketed treatments. At the same time, an allegation is not proof of wrongdoing, and fairness requires that professionals have meaningful opportunities to understand and respond to concerns.

BoardWise is well-positioned to help bridge that gap: a technology-enabled, privacy-conscious process for translating complicated regulatory correspondence into organized, factual, and appropriately reviewed action.

Our aim is not to replace attorneys or licensing boards. It is to make the journey more intelligible for the clinicians whose professional licenses, businesses, and livelihoods are affected.

If you are a licensed nurse, advanced practice provider, medical director, or other professional facing a licensing inquiry arising from medical aesthetics or elective IV treatment, you do not have to start from a blank page.

Get started with BoardWise: Open the guided intake to explore educational guidance, document organization, and available independent attorney review.

Research sources and further reading

1. American Med Spa Association , Medical Spa State of the Industry Report (2026). Trade-association industry revenue estimates; not a federal census.

2. California Department of Consumer Affairs / BRN , FY 2026–27 Investigations Budget Change Proposal. Workload history and the Med Spa/IV Hydration Task Force discussion, pp. 2–3.

3. California Board of Registered Nursing , Sunset Review 2026. Scope-of-practice, compounding, and investigative challenges.

4. California DCA , Annual Report 2024–25. Multi-board medspa/IV task-force activity.

5. Texas Legislature , Occupations Code Chapter 172, Elective Intravenous Therapy. Statutory definitions and delegation rules.

6. Texas Medical Board , Who Can Do IV Hydration?. Agency interpretation of elective IV ordering and administration.

7. Texas Board of Nursing , Nursing Practice Frequently Asked Questions. RN ownership, orders, and LVN restrictions for elective IV hydration.

8. Virginia Department of Health Professions , Guidance Document 76-1, Effective October 8, 2026. Eight-page joint regulatory guidance.

9. Virginia Regulatory Town Hall , Official Guidance Register Entry. Effective date and status.

10. Medical Board of California , Medical Spas. Qualified personnel and cosmetic medical treatment.

11. California BRN , The Complaint Process. Jurisdiction, complaint intake, and case progression.

12. California BRN , What Is the Enforcement Program?. Investigation, formal action, hearings, probation.

13. California BRN , Enforcement FAQs. Types of outcomes and investigative procedure.

14. California BRN , Disciplinary Actions and Reinstatements. Disciplinary terminology and relevant factors.

15. FDA , November 2023 Intergovernmental Working Meeting on Drug Compounding. Cross-agency concerns involving IV hydration operations.

16. FDA , Responses to 2023 Intergovernmental Meeting Action Items. Collaboration among FDA and state boards.

17. CDC , Preventing Unsafe Injection Practices. Sterile preparation and injection safety.

18. CDC , Infection Prevention for Outpatient Settings, updated 2025. Minimum ambulatory safety expectations.

19. FDA , August 27, 2026 Glutathione Injectable Compounding Alert. Ingredient suitability and reported adverse events.

20. FDA , Reminder on Ingredients Suitable for Sterile Compounding. Risks of food-grade NAD+ components.

21. FDA , October 13, 2026 Warning Letter: Calibrate IV Hydration. Unapproved biologic product marketing allegations.

22. FTC , Health Products Compliance Guidance. Substantiation of health-related advertising.

23. FTC , First Action Targeting IV Cocktail Therapy Marketer. Historical example of federal action over unsupported claims.

24. BoardWise , Start. Educational and organizational intake for licensed professionals.

Research note: This article was prepared as of November 1, 2026. Federal and state source materials address different jurisdictions, clinical settings, reporting periods, and enforcement stages. The cited California workload statistics are agency-wide and must not be interpreted as medspa-specific complaint rates, probabilities of discipline, or evidence of BoardWise outcomes. Industry revenue figures are attributable to the trade association that reported them. Hypothetical scenarios are illustrative only.

Disclaimer: This article provides general education, not medical or legal advice. Requirements differ by state, license, service, clinical setting, and date. Check current official notices, laws, board rules, and competent professional counsel. BoardWise is not a law firm and does not provide legal advice; independent network attorneys establish separate attorney-client relationships. No licensing outcome is promised or guaranteed.